
 
 
 
 
 
 
 
 
   
 1) 
 BHWA1_RSO2195 (hemolysin III) 
 ATGGAGAAAAGTGCTTTTTATATAGATATACAAAACAAATCTAATAAATCAAAAAAGATAGGGGAGC 
 TATACTCAGCAATATCCCATGGCATAGGAGCTTTACTTGGTATTGCTGGACTTGTTCTTATGCTTGTAA 
 AAATAAAAATGAATCCTATACCTATAATTATTTATGGAGTTGGTATAATCTTTTTATATACATTCAGTT 
 CTTTATATCATTTCTTTCCTGACGGTAAAATAAAACAAATATTTAGAAAATTTGATCACATAGGAATAT 
 ATGTGTTTATAGCCGCAACTTATACTCCAGTTTGTATATTTTCACTTCCTAGAAACATAGGAATACCAA 
 TATTATCAGTAATATGGTCTTGTGCTTTGATAGGTATATTATCTAATACAGTTATAAAATATAAAAATA 
 TTGTTCTAAGGCTAGTTTTATATATATTAATGGGCTGGATAATAATATTTGCATTCAAACCATTAATGA 
 ATAGATTTGATATTTTGCATTTAAATTGGCTTATATGGGGAGGAATATTTTATACTATAGGTGCTTTCT 
 TATATGCTTTAGGTAAAAAATGCAATGATAAAACTAAGCAATTCACTCATGATATTTTCCAT (SEQ ID 
 NO: 2) 
 Figure 4 
 WO 2017/118581 
 PCT/EP2016/082386 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 days post challenge vaccinated daily non-vaccinated daily vaccinated cumulative non-vaccinated cumulative 
 Figure 3 
 WO 2017/118581 
 PCT/EP2016/082386 
 1,6 -| j- 10 cumulative average fecal score 
 1/11 
 Figure 1 uoiithosqe 
 WO 2017/118581 
 PCT/EP2016/082386 
 1. An isolated strain of Brachyspira hyodysenteriae (B. hyodysenteriae) comprising the genes encoding the polypeptides comprising the following amino acid sequences: SEQ. ID NO:10, SEQ ID NO:11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15, or a sequence having at least 95% identity thereto. 
 
     
 2/11 fecal score fecal score 
 2. The strain according to claim 1, wherein said genes comprise the following nucleic acid sequence: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, or a sequence having at least 95% identity thereto. 
 
     
 3/11 daily average fecal score 
 3. The strain according to claims 1 or 2, wherein said strain further comprises the plasmid encoded virulence associated genes BHWA1_O2678, BHWA1_O2679, BHWAl_02680 and BHWA1_O2681. 
 
     
 4/11 
 BHWA1_RSO2885 (hemolysin activation protein) 
 ATGCGTTTAGTAAGAGAAAAAAAAATAAAAGAAGAGGATAAAAAGTATTGGGAAAAATCAAGTTCT ATGATACCTACCCTATTAGTTGGCAATAACATAGTAAATATATCTGCGAGTTCTATTATAACAGTATTT GCAGTAAGGCTTGCTGATATTCTGCCGCATGTATCAACAAATATAATGGTTACAATATCAACTGCTAC AATAACAATACTTATTATTATATTTGGTGAAATACTGCCAAAAGTCTTAATGAGAGTAAATGCTGAAA AAGTAATGCCTTATCTTTTATACTTTATGAAATTTTGCCATTTTATATTCAAGCCTATAACCTTTTTAAT GGATAAAGTAACTACTTTTATAATGAATTATTTCGTTCCTAAAAGATTAAGAGATGCTGAAAAAAGAA GTGCATTATCAAGTATGGACGATATAACAACAATAATACATTTGGGGCATAAAGAAGGTATAATAAA AGAATATACACATGAAATGCTTACAGGTGTAATAGATTTCAGAAATAAAACTGTAGAAGAAATAATG ACTCCTCGTGTTGATATGGTATGTATTGAGGCTGAAACTGATGTAAATGAAATAATAAAACTTACTGT AGAAACAGGGCTTTCAAGATTTCCGGTTTATGAGGAAACTGTTGATCATATAATAGGAATTTTCCATA CTAG AG CTTTATTTAAAG AGTATGTTAAAGG CG G CG G AAAAATG AATAAAATAAAAAAG AAAG C AA TAGATTATATAATGCTTCCCTACTTTGTACCTGAAACTAAAACTATAAGCAGCTTATTTAGTGATATGC AAAAGAAAAAACTTCAGATGGTAATTACTATTGATGAATACGGCGGAACTGCTGGGCTTGTTACTAT GGAAGATATAATAGAAGAGATAATGGGTGATATAGAAGATGAAAGTGATAAAAAAGAAGCTGATG TAATAAGATTTAAGGGAAAAAGAATTATAATAAATGGAAATGCTTCTATAGAAGATGTCAACAAAAC TTTAAAATTAGAATTAGAGCATGAAGAATATCAAACTATAGCAGGATATGTTATTGATATGCTTGATC ATATACCTGAAACAAATGAGAGATTCATATTAAAAGGATATAGAGTAAGAATAATGAAAGTTGAAG ACAGAAGAATAGTTGAAATGGAATTTACTCCTATAAAATTTGCAAGAACAAATGAAAGTGATAATAT TGATATACAAGAGACATCTGATTCAGAAAAAAATGATTTAGAAATTTTAAATGAATAA (SEQ ID NO: 
 4. The strain according to any one of claims 1 to 3, wherein said strain is the strain deposited on 23 October 2015 at the Belgian Co-ordinated Collections of Micro-Organisms under BCCM Deposit No. LMG P-29184. 
 
     
 5/11 
 BHWAl_RS09085 (hemolysin III channel protein) 
 ATG AATG CTG ATTTG AATAATAATATAGTAAAG AATTCTGTTTCTAAG ATAAG CG CTGTTATATGCAT 
 AATATGTG CTAGTTCGG CAATAGCTGTCTTAGTG CTTTTAATAATTAATTCTAAAACTG CAAGGG AAA 
 TTACTTCATTTTCTCTATACTCAAGTTTTTTAACAATATTTTATATAATAAATTCGATATATCATTTTTTT 
 CCTTTTAACAATAAAGCAAAAAAAGTTTTTTATATATTATCCCATGCATTTTTTATTATGATGATATGG 
 GGTATATACATTCCTCCATGCCTAATATCATTACAAAATGGATGGGGATGGAGTTTCTTTGGTATTAT 
 TACAGGTTTATGTGCATTAGGCATCACATTAAGAAGCGTATTCGGATACAGATGGCGTGGTGCTACA 
 GAAACTATATATTATTTTCTATTAAATTGGGTTTGGCTTATAGCAATTTCAAAAATATCTACTGCTGTA 
 G GTG A ATATG GAG C A ATATT ATATTTA AC AG GTTTTCTTCTG CTC A AT ATAG C A ATG GTATTTT AC AG 
 ACTCGCTATGTATGAAGCCAATAGAAGATATACTTTATTTTTACCTTTATTTTATTCGCTTTTAATAATA 
 TCAAATATATGCCATGCAGTATTTATGTTTAGATATGTTGCTAACATTTTCTAA (SEQ ID NO: 3) tlyA 
 TATACTGAAACTTTTGAATCAGTTTATATAACTTCAAATATATTAGAAAGCAATCATACTCAAATGCTT 
 TTAAAAGTAAATATGAGAGATAAAGAAAGAAATTCTCTTTCTATAATAAAATCTTTCCTTGGATTATA 
 ATACTAATATAAATG CG ATTAG ATG AATATGTG CATAGTG AATG CTATACAG AAAG CAG ATCTAAAG 
 CACAGGATATAATACTAGCCGGTTGTGTTTTTGTTAATGGAGTAAAGGTAACTTCTAAGGCTCATAAA 
 ATAAAAGATACTGATAATATAGAAGTTGTTCAGAATATAAAATATGTATCAAGAGCTGGAGAAAAAT 
 TAGAAAAGGCGTTTGTAGAATTTGGAATATCTGTAGAAAATAAAATATGTTTAGATATAGGAGCTTC 
 TAC AGG AG G ATTTAC AG ATTGTCTG CTTAAG C ATG GTG CTAAAAAAGTTTATG CTCTTG ATGTAGG A 
 CATAATCAGCTAGTTTATAAACTTCGTAATGATAATAGGGTAGTGTCAATAGAAGATTTCAATGCCAA 
 AGATATAAATAAAGAAATGTTCAATGATGAAATCCCATCTGTAATAGTAAGTGACGTATCATTTATAT 
 CAATAACAAAAATAGCACCAATCATATTTAAAGAATTAAATAATTTAGAGTTTTGGGTAACTTTAATA 
 AAACCACAATTTGAAGCTGAAAGAGGTGATGTTTCAAAAGGCGGTATAATACGAGATGATATACTTA 
 GAGAAAAAATATTAAATAATGCTATTTCAAAGATAATAGACTGCGGATTTAAAGAAGTTAATAGAAC 
 CATCTCTCCTATAAAAGGTGCTAAAGGTAATATAGAATATTTAGCTCATTTTATTATTTAATCATTTTCT 
 ATTTTATGTGTATTTCTCTGTTTATATATTTCATATTCTTTATA (SEQ ID NO: 4) 
 Figure 4 - continued 
 WO 2017/118581 
 PCT/EP2016/082386 
 5 comprising the steps: (a) obtaining a sample of B. hyodysenteriae; and (b) determining the presence or absence of the nucleic acid molecules as depicted in SEQ. ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:5 and SEQ ID NO: 6, and/or the expression of corresponding mRNA or protein products, wherein the presence of said nucleic acids or expression of corresponding mRNA or protein is indicative of a vaccine strain of B. 
 5. A composition comprising at least one strain of B. hyodysenteriae according to any one of claims 1 to 4, and a pharmaceutically acceptable carrier, excipient and/or diluent. 
 
     
 6/11 tlyB 
 TAATAAGGACAATTCTCATAAGACTAATACTGCATCATCTAGTAAGACTAACATAAATGTTGTTAATGTAGCTA 
 ATAGTAGTTTTATTTAAAATTTAAAACCTATAATAGAAATTCTAAATTATACATTAGCATTCCTTTATGTTAATGT 
 ATAATTTTGTTTTATTTATAATAGTATTTCTATTATATCCGATAATGATTATTAAAATATTTTATATACGTAAAATA 
 TAATACAGGATTATAATATGTTTCAATTTCATTTAACAAGCAAAGCAAAAAAGGTAATAGAATTATATGCTCAG 
 GAAGAAGCAAAAAGATTAAATCATGATATGGTTACACCTGAACATATACTTTTGGGGCTTCTTCATGAATCAGA 
 GGCTTTGGCAACACGTGTTTTGATGAGATTGAAAATTGATTTGGACAGACTTAAATTAGAATTAGAATCAGCTA 
 TGGTAAAATCTTCAACTACAAAAGTATTTGGAACTTTACCTACAGCTCCAAGAGTACAGAAACTTATAAGCAGA 
 TCTGCTGAAGAGGCTAGGGCTTTAAGTCATAACTATATAGGTACTGAACATTTACTTCTTGGACTTCTAAGAGA 
 AGAAAGTGGTACAGCTTATAATGTACTTACAAGTATGGGGCTTGAGCTTACTATATTAAGACAAGAAATATTA 
 AAAATGCTTGGTGTTGCTGGAAGTAATATTTCTTCTATGGAACAGACAAGTCAGGAAGATAATGTAAAAAAGG 
 TAAAAACACCTACTTTAGATCAATTTGCCAGAGATTTAACTAAAATGGCTAGAGACAAGGCTTTAGACAGAGTT 
 ATAGGCAGAGAAAATGAAGTAATGAGAGTTGTTCAGATTTTATCAAGAAGAAAGAAAAATAATCCTATACTTC 
 TTGGTGAGCCTGGTGTAGGTAAAACAGCTATAGTAGAGGGACTTGCTGAAAAGATAGTAGCTGCTGATGTAC 
 CTGATATACTTCTAAAAAAACGTGTATTAACTTTAGATTTGTCTTCAGTTGTTGCTGGTACAAAATACAGAGGTG 
 AATTTGAAGAGAGAATAAAAAACATAGTTTTAGAAATAAAAAAAGCTAGTAATATTATTATATTCATAGATGA 
 GCTTCATACATTAATAGGGGCAGGTGGTGCTGAAGGTGCTTTAGATGCTGCTAATATGTTAAAGCCGGCACTT 
 TCAAGAGGCGAGATTCAATGTATAGGTGCCACTACTATAAATGAATATAAAAAATATATAGAAAAAGACGGTG 
 CTTTGGTTAGAAGATTCCAGCCTATAAATGTTGAAGAGCCTAGTATAGAGGATACTATTGAAATATTGAATGGT 
 ATCAAAGGTAAATATGAAGAACATCATAAAGTAAAATATACTGATGAAGCAATAAATGCTGCTACTGTATTGA 
 GTAAGAGATATATTTTTGAAAGACATTTGCCTGATAAAGCTATAGACTTAATAGATGAGGCAGGTTCAAGAGC 
 AAGACTTCTTAATATGACAAGACCTCAGGAGTTTAAAGATTTAGAAAAGAAAATAGAAGAGCTTAATCAGCAA 
 AAGAAAAGAGTTGTTGAGAGTCAGAATTTCGAAGATGCTGCTAAAATAAGAGATGAAATTACTTCTTTACAGG 
 AAGAGCTTTCTAAAAAAGAAGAAAAATGGCGTGAAGAAAGAGAAAAGATAGAAACATTTATTGAAGAAGATG 
 ATATAAGACATGTTATATCAGAAATAACTAATATACCTATAAAAAGATTATTAAACTCAGAAAGTAAAAGACTT 
 ATAGGTATGGAAGAAGAATTGCATCAGAAAGTCGTAGGACAGAAAGAAGCTATATCTTCTATATCTAAGGCTA 
 TAAGAAGAAGCAGAGCAGGACTTAAAACATCAAAAAGACCTCTTGGAAGTTTTATTTTCCTGGGACCTACAGG 
 TGTTGGTAAAACTGCTTTAGCTAAAGTTCTTTCAGAGTTTATGTTTGGAGACAGCGATGCTCTTATCAGAATAG 
 ATATGAGTGAGTTTATGGAAAAGTTTGCGGTAAGCAGACTTATAGGAGCTCCTCCTGGATATGTTGGTTATGA 
 AGAGGGAGGCGGACTTACTGAAAAGGTGAGAAGAAAGCCTTATTCTCTTATACTTTTTGATGAAATAGAAAAA 
 GCTCATCCTGATGTTACTAATATACTTTTACAAGTACTTGAAGAAGGACAGCTTACTGATAATTTTGGAAGAAA 
 AGTTGATTTTTCAAATACTATTATAATAATAACAAGTAACTTAGGTGCAAGAGATATTGTAAAAGGAAGTTCTT 
 TAGGATTTAATGCTGTTGGAAGCGAAAAAGATGCTAATGATATTAAAAATTTTGCTTTAGAAGAATTAAAACA 
 GAATTTTAATCCTGAGTTTTTAAATAGAATTGATGATATCATAGTATTCCATACTTTAAGTAAAGAGGATTTGAA 
 AGATATTATTAATATAATGCTTAAAGAGCTTAATGAAGCTATTAAAGAAAGAAATATTGTTATTAATTTAAGCG 
 AAGAAGCTAAGAATTATATCATAGATAAAGGATTCGATAAGAAGTATGGTGCTAGAAGTTTAAGAAGGGCTAT 
 ACAGAAAGAGATAGAGGATTATGTGAGTACCGAAATATTATTCGGTAATATTGAAGATGGTGATACTATTAAC 
 GTTGATGCTAATGATGGCTCTTTGATATTTTCTTATGATAAGTCAGTTAAGACTGAGAATAAGGAATTATCTAA 
 AAGTTAG (SEQ ID NO: 5) 
 Figure 4 - continued 
 WO 2017/118581 
 PCT/EP2016/082386 
 6. Use of strain or composition according to any one of claims 1 to 5, in the manufacture of a vaccine. 
 
     
 7/11 tlyC 
 TAAAAGGGATACATCATAATTATACTAGAAAATCATTAATGGAAAATAATAAGAAAATGAAGGAATT ATACAAAAAAGTGATAAAAACAATAAAAGAAAATAAATCATAATTTAAGGATATATATAAAATGCCA ATAAAAAAATTAATATCTAAGATAGTGAAAAAAAAAGATAGTGATACTGAAAAAAATAATTATATAA ATTTATCCGCATTAACAGAAGCAGAAAGAGAAATTATAACTAATACTATAGAATTGAAATCAAAGAG CGTAAGAGAAATAATGGTGCCTAGGGTTGATGTTGTTATGATACCTATGGAATCTTCTTATGATAAG GTTATAAAGGCTTTTAATAGAGATAGAAATTCCAGAATTCCTGTATACAAAGACGGCATAGATGATA TAGTAGGGGTTTTGTATGTAAAAGATTTGATTGATGCAGAAGAAAAAAATTTCTCACTTAAAAAAATT CTACATAAACCTTTATTCGTACCAATATCAATTTCATTAATGGAATTATTAAAAAATTTCAGAGAAAAG CAAATTCATATTGCTATGGTTGTTGATGAATATGGCGGATTTTCTGGTATTGTTTCTATGGAAGATGT GCTTGAGCAGATTATAGGTGATATTAGAGATGAATACGATGAAGAAGACGAAGAAATAAAGAGCAA TGATGATGGAACATATTTAGTTGATGCAAGAACTAGAATAGATGATTTTAATAAATATGAGATACTTC CGCCTATACCGGATGATGAGGCAGATACAGTTGGAGGATTTTTATTTTCATACTTGGGCAGGCTTCCT AAAAGAAATGAGGATATAGAATATAATGGATATTCATTTACTGTAGTTGGTAAAAGCGGAAATATTG TTACTAAAATAAGAATAGAAAAATTAAAAAAAGATAATACAGCAAAAAATAAAGATTA (SEQ ID NO: 6) hlyA 
 CGGTTGACGGCGGAATGTCAATGTAATTATAAAAAAGTATATAATGTGTTTAAAAACACTTTATTAAT AAACAATATACAATTTAAGGAGAATTAAAAATGGCATTAATCGATGAAATTAAAGATGTTGTTGCTA ATCAATTAAACATCTCAGACAAAAGTAAAATCACTGATACAGCTTCTTTCGTAGATGATTTAAACGCT GATTCACTTGATTTAGTAGAATTAATCATGGAATTAGAAAAACGTTATGAAATCAAAATTCCTCAAGA AGATCAAGAAAAAATCAAAAATGTAGCTGATGCTGCTAAATACATTGAAGAACATAAAAAATAATTA TACTATTTAAATTTCCCGTAAATAGAATTATGTCTTTTACGGGAAATTTTTCGATATAGTTCAAAATCA TAGGAGTTTTATATATGAGTGAACGTAGAGTTGTAATTACGGGGCTTGGAATAGTAAGTTC (SEQ ID NO: 7) 
 Figure 4 - continued 
 WO 2017/118581 
 PCT/EP2016/082386 
 7. The strain or composition according to any one of claims 1 to 5, for use as a medicament. 
 
     
 8/11 
 NADH oxidase (nox) 
 CTATGCTAGTCCTGAAAGTTTGAGAGGTGAAGGCATCGATGTTTATATGGGACATGATGTTACTAAA 
 ATAGACTGGGCTAACAAAAAATTATGTGTAAAAGAACTAAAAACAGGAAAAGAGTTTGAAGACACT 
 TACGATAAACTTATTCTTGCTACTGGTTCTTGGCCTGTAACTCCTCCTATCGAAGGCTTAAAACAAGAA 
 G G AACTACTTACG G ACTTAAAAAAG GTATTTTCTTCTCTAAG CTTTATC AG C AAG G AC AAG AAATTAT 
 TGATGAAATAGCTAAACCAGATGTTAAAAAAGTTATGGTAGTTGGTGCTGGATACATAGGTGTTGAA 
 CTTATAGAAGCATTCAAAAACCATGGTAAAGAAGTTATCTTAATGGAAGCTATGCCTAGAGTTATGG 
 CTAACTACTTTGATAAAGAAATCACTGATGAAGCTGAAAAAAGAATCAAAGAAGCTGGCATAGAAAT 
 GCATTTAGGTGAAACTGTTAAGAAATTTGAAGGTGATGACAGAGTTAAAAAAGTTGTTACTGACAAA 
 GGTTCTTATGATGTAGATATGGTAGTTATGTCTGTTGGTTTCAGACCTAATAATGAACTTTATAAAGA 
 TTATTTAGAAACTTTACCTAATGGTGCTATTGTAGTAGATACTACTATGAAAACTACTAAAGATCCTG 
 ATGTATTTGCTATAGGTGACTGTGCTACTGTATATTCAAGAGCTTCTGAAAAACAAGAATATATTGCT 
 TTAGCTACTAATGCTGTAAGAATGGGTATTGTTGCTGCTAATAATGCTTTAGGAAAACATGTTGAATA 
 TTGCGGTACTCAAGGTTCTAATGCTATTTGTGTATTTGGATACAATATGGCTTCTACTGGTTGGTCTG 
 AAGAAA CTGCTAAGAAAAAAGGATTAAAAGTAAAATCTAACTTCTTCAAAGATTCTGAAAGACCAGA 
 ATTTATGCCTACTAATGAAGATGTTTTAGTAAAAATCATTTATGAAGAAGGCAGCAGACG (SEQ ID 
 NO: 8) 
 16S rRNA 
 CGCATATACTCTTGCTACATAAGTAGAGTAGAGGAAAGGAGCAATCCGCTTTACGATGAGCCTGCGG 
 CCTATTAGCCTGTTGGTGGGGTAACGGCCTACCAAAGCTACGATAGGTAGCCGACCTGAGAGGGTG 
 ACCGGCCACATTGGGACTGAGATACGGCCCAGACTCCTACGGGAGGCAGCAGCTGAGAATCTTCCA 
 CAATGGACGAAAGTCTGATGGAGCGACATCGCGTGAGGGATGAAGGCCTTCGGGTTGTAAACCTCG 
 GAAATTATCGAAGAATGAGTGACAGTAGATAATGTAAGCCTCGGCTAACTACGTGCCAGCAGCCGC 
 GGTAATACGTAGGAGGCAAACGTTGCTCGGATTTACTGGGCGTAAAGGGTGAGTAGGCGGACTTAT 
 AAGTCTAAGGTGAAAGACCGAAGCTCAACTTCGGAAACGCCTCGGATACTGTAAGTCTTGGATATTG 
 TAGGGGATGATGGAATTCTCGGTGTAGCGGTGGAATGCGCAGATATCGAGAGGAACACCTATAGCG 
 AAGGCAGTCATCTGGGCATTTATCGACGCTGAATCACGAAAGCTAGGGGAGCAAACAGGCTTAGAT 
 ACCCTGGTAGTCCTAGCCGTAAACGTTGTACACTAGGTGCTTCTATTTAAATAGGAGTGCCGTAGCTA 
 ACGTCTTAAGTGTACCGCCTGAGGAGTATGCCCGCAAGGGTGAAACTCAAAGAAATTGACGGGTCC 
 CCGCACAAGTGGTGGAGCATGTGGTTTAATTCGATGATACGCGAAAAACCTTACCTGGGTTTGAATT 
 GTAAGATGAATGATTTAGAGATAAGTCAGACCGCAAGGACGTTTTACATAGGTGCTGCATGGCTGTC 
 GTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTCACCCTTTGTTGCTAC 
 CGAGTAATGTCGGGCACTCTTAGGGGACTGCCTACGTTCAAGTAGGAGGAAGGTGGGGATGATGTC 
 AAGTCCTCATGGCCCTTATGTCCAGGGCTACACACGTGCTACAATGGCAAGTACAAAGAGAAGCAAG 
 ACCGCGAGGTGGAGCAAAACTCAAAAAAGTTGCCTCAGTTCGGATTGGAGTCTGAAACTCGACTCCA 
 TGAAGTTGGAATCACTAGTAATCGTAGATCAGAACGCTACGGTGAATACG (SEQ ID NO: 9) 
 Figure 4 - continued 
 WO 2017/118581 
 PCT/EP2016/082386 
 8. The strain or composition according to any one of claims 1 to 5, for use in the treatment or prevention of an infection with B. hyodysenteriae in a subject. 
 
     
 9/11 
 BHWA1_RSO2885 (hemolysin activation protein) 
 MRLVREKKIKEEDKKYWEKSSSMIPTLLVGNNIVNISASSIITVFAVRLADILPHVSTNIMVTISTATITIUIIFG 
 EILPKVLMRVNAEKVMPYLLYFMKFCHFIFKPITFLMDKVTTFIMNYFVPKRLRDAEKRSALSSMDDITTHH 
 LGHKEGIIKEYTHEMLTGVIDFRNKTVEEIMTPRVDMVCIEAETDVNEIIKLTVETGLSRFPVYEETVDHIIGI 
 FHTRALFKEYVKGGGKMNKIKKKAIDYIMLPYFVPETKTISSLFSDMQKKKLQMVITIDEYGGTAGLVTME 
 DIIEEIMGDIEDESDKKEADVIRFKGKRIIINGNASIEDVNKTLKLELEHEEYQTIAGYVIDMLDHIPETNERFI 
 LKGYRVRIMKVEDRRIVEMEFTPIKFARTNESDNIDIQETSDSEKNDLEILNE (SEQ ID NO: 10) 
 BHWA1_RSO2195 (hemolysin III) 
 MEKSAFYIDIQNKSNKSKKIGELYSAISHGIGALLGIAGLVLMLVKIKMNPIPIIIYGVGIIFLYTFSSLYHFFPD GKIKQIFRKFDHIGIYVFIAATYTPVCIFSLPRNIGIPILSVIWSCALIGILSNTVIKYKNIVLRLVLYILMGWIIIFA FKPLMNRFDILHLNWLIWGGIFYTIGAFLYALGKKCNDKTKQFTHDIFHIFVLMGSFCHYWFLYSYVIN (SEQ ID NO: 11) 
 BHWAl_RS09085 (hemolysin III channel protein) 
 MNADLNNNIVKNSVSKISAVICIICASSAIAVLVLLIINSKTAREITSFSLYSSFLTIFYIINSIYHFFPFNNKAKKV FYILSHAFFIMMIWGIYIPPCLISLQNGWGWSFFGIITGLCALGITLRSVFGYRWRGATETIYYFLLNWVWLI AISKISTAVGEYGAILYLTGFLLLNIAMVFYRLAMYEANRRYTLFLPLFYSLLIISNICHAVFMFRYVANIF (SEQ ID NO: 12) 
 TlyA 
 MRLDEYVHSECYTESRSKAQDIILAGCVFVNGVKVTSKAHKIKDTDNIEVVQNIKYVSRAGEKLEKAFVEFG ISVENKICLDIGASTGGFTDCLLKHGAKKVYALDVGHNQLVYKLRNDNRVVSIEDFNAKDINKEMFNDEIP SVIVSDVSFISITKIAPIIFKELNNLEFWVTLIKPQFEAERGDVSKGGIIRDDILREKILNNAISKIIDCGFKEVNR TISPIKGAKGNIEYLAHFII (SEQ ID NO: 13) 
 Figure 4 - continued 
 WO 2017/118581 
 PCT/EP2016/082386 
 9. The strain or composition according to any one of claims 1 to 5, for use in treating, reducing the symptoms/severity of, or preventing a diarrheal disease, in particular swine dysentery in a subject. 
 
     
 10/11 
 TlyB 
 MFQFHLTSKAKKVIELYAQEEAKRLNHDMVTPEHILLGLLHESEALATRVLMRLKIDLDRLKLELESAMVKS 
 STTKVFGTLPTAPRVQKLISRSAEEARALSHNYIGTEHLLLGLLREESGTAYNVLTSMGLELTILRQEILKMLG 
 VAGSNISSMEQTSQEDNVKKVKTPTLDQFARDLTKMARDKALDRVIGRENEVMRVVQILSRRKKNNPILL 
 GEPGVGKTAIVEGLAEKIVAADVPDILLKKRVLTLDLSSVVAGTKYRGEFEERIKNIVLEIKKASNIIIFIDELHT 
 LIGAGGAEGALDAANMLKPALSRGEIQCIGATTINEYKKYIEKDGALVRRFQPINVEEPSIEDTIEILNGIKGK 
 YEEHHKVKYTDEAINAATVLSKRYIFERHLPDKAIDLIDEAGSRARLLNMTRPQEFKDLEKKIEELNQQKKR 
 VVESQNFEDAAKIRDEITSLQEELSKKEEKWREEREKIETFIEEDDIRHVISEITNIPIKRLLNSESKRLIGMEEE 
 LHQKVVGQKEAISSISKAIRRSRAGLKTSKRPLGSFIFLGPTGVGKTALAKVLSEFMFGDSDALIRIDMSEFM 
 EKFAVSRLIGAPPGYVGYEEGGGLTEKVRRKPYSLILFDEIEKAHPDVTNILLQVLEEGQLTDNFGRKVDFS 
 NTIIIITSNLGARDIVKGSSLGFNAVGSEKDANDIKNFALEELKQNFNPEFLNRIDDIIVFHTLSKEDLKDIINI 
 MLKELNEAIKERNIVINLSEEAKNYIIDKGFDKKYGARSLRRAIQKEIEDYVSTEILFGNIEDGDTINVDANDG 
 SLIFSYDKSVKTENKELSKS (SEQ ID NO: 14) 
 TlyC 
 MPIKKLISKIVKKKDSDTEKNNYINLSALTEAEREIITNTIELKSKSVREIMVPRVDVVMIPMESSYDKVIKAF NRDRNSRIPVYKDGIDDIVGVLYVKDLIDAEEKNFSLKKILHKPLFVPISISLMELLKNFREKQIHIAMVVDEY GGFSGIVSMEDVLEQIIGDIRDEYDEEDEEIKSNDDGTYLVDARTRIDDFNKYEILPPlPDDEADTVGGFLFS YLGRLPKRNEDIEYNGYSFTVVGKSGNIVTKIRIEKLKKDNTAKNKD (SEQ ID NO: 15) 
 HlyA 
 MALIDEIKDVVANQLNISDKSKITDTASFVDDLNADSLDLVELIMELEKRYEIKIPQEDQEKIKNVADAAKYI EEHKK (SEQ ID NO: 16) 
 NADH oxidase (nox) 
 YASPESLRGEGIDVYMGHDVTKIDWANKKLCVKELKTGKEFEDTYDKLILATGSWPVTPPIEGLKQEGTTY GLKKGIFFSKLYQQGQEIIDEIAKPDVKKVMVVGAGYIGVELIEAFKNHGKEVILMEAMPRVMANYFDKEI TDEAEKRIKEAGIEMHLGETVKKFEGDDRVKKVVTDKGSYDVDMVVMSVGFRPNNELYKDYLETLPNGA IVVDTTMKTTKDPDVFAIGDCATVYSRASEKQEYIALATNAVRMGIVAANNALGKHVEYCGTQGSNAICV FGYNMASTGWSEETAKKKGLKVKSNFFKDSERPEFMPTNEDVLVKIIYEEGSRR (SEQ ID NO: 17) 
 Figure 4 - continued 
 WO 2017/118581 
 PCT/EP2016/082386 
 10 log # b. hyo / g feces 
 Figure 2 
 WO 2017/118581 
 PCT/EP2016/082386 
 10 hyodysenteriae. 
 14. An in vitro method of diagnosing avirulent B. hyodysenteriae colonization in a subject, comprising the steps of: (a) obtaining a sample from said subject; and (b) determining the presence or absence of one or more nucleic acid sequences substantially identical to one or more of the nucleic acid sequences depicted in SEQ ID NO: 1-6, and/or the expression of 
 15 corresponding mRNA or encoded protein products, wherein the presence of said nucleic acids or corresponding mRNA or protein products indicates the presence of avirulent B. hyodysenteriae colonization in the subject. 
 WO 2017/118581 
 PCT/EP2016/082386 
 10. The strain or composition for use according to any one of claims 7 to 9, wherein the strain or composition is administered orally or parentally to the subject. 
 11. The strain or composition for use according to any one of claims 8 to 10, wherein the subject is a pig. 
 WO 2017/118581 
 PCT/EP2016/082386 
 12. A kit for vaccination of an animal against B. hyodysenteriae infection comprising: (a) a composition comprising at least one vaccine strain according to any one of claims 1 to 4; and (b) instructions for vaccinating an animal. 
 13. An in vitro method of identifying a candidate vaccine strain of B. hyodysenteriae 
 
     
 11/11 cumulative average fecal score vaccinated non-vaccinated 
 Figure 5 
 
   
 
 
 
 
 
 
 
 
